Gene Therapy and Adenosine Deaminase Deficiency

Why a hereditary enzyme defect may require molecular treatment

Inherited disease can arise when a gene variant reduces the amount or function of a protein needed for normal cell physiology. Adenosine deaminase, or ADA, is an enzyme involved in the metabolism of purine nucleosides. Severe loss of ADA activity permits the accumulation of metabolites harmful to developing lymphocytes. Because lymphocytes are essential for defending against infectious agents, severe ADA deficiency can cause a form of severe combined immunodeficiency, often abbreviated ADA-SCID. Affected children can have profound defects in both cellular and antibody-related immunity and may experience life-threatening infections without effective treatment.

Not every ADA-SCID case arises from deletion of the entire ADA gene; different disease-causing variants can disrupt enzyme production or activity. The biological chain is important: an altered gene affects enzyme function, altered metabolism damages lymphocyte development and survival, and impaired lymphocytes lead to immunodeficiency. Gene therapy aims to address the deficient cellular function rather than only reduce symptoms of infections after they occur. It is one of several possible treatment approaches, each with different limitations.

What the term gene therapy means

Gene therapy refers to treatment approaches that deliver genetic information or modify genetic function in a person's cells to correct, compensate for or otherwise address disease. In gene addition, a functional copy of a gene is supplied so that cells can make the required protein, without necessarily removing or directly repairing the original disease-causing gene. In gene editing, targeted molecular systems may alter genomic DNA itself. Other approaches can use RNA-level regulation or genetically modified immune cells. These are related technologies but should not be described as one uniform procedure.

The source describes the early clinical use of gene therapy in a child with ADA deficiency in 1990. In a historical ex vivo approach, lymphocytes were collected, cultured outside the body, given a functional ADA coding sequence through a modified viral vector, and returned to the patient. These cells could provide ADA activity but were not all permanently self-renewing. Repeat treatment could therefore be required as corrected cells disappeared. This example demonstrates both the promise of gene addition and the limitation of choosing a short-lived target population.

How an ex vivo approach works conceptually

Ex vivo means that living cells are manipulated outside the body before being returned. Cells are collected from the patient and assessed for suitability, genetic material is introduced through a carefully selected delivery system, and the modified cells are checked for identity and functional gene expression before clinical infusion. In the historical lymphocyte approach, the modified cells express ADA but can have limited persistence. More durable approaches can target haematopoietic stem or progenitor cells, which can give rise to many generations of immune cells. The central scientific requirement is sustainable enzyme expression in the relevant cell lineages.

Viral vectors and safety considerations

Viruses naturally deliver genetic material to host cells. Engineered viral vectors can make use of this delivery capability while removing or altering features required for harmful uncontrolled replication. Some vectors integrate genetic material into the host genome, supporting longer-term expression, but integration can also disrupt nearby genes or influence cell-growth regulation. Other vector types may not integrate efficiently and can be less durable in dividing cells. Choice of vector, cell population and expression pattern are therefore critical safety and efficacy decisions rather than interchangeable technical details.

Gene addition does not automatically become permanent just because a DNA sequence enters a cell. The engineered cell must survive, retain an effective gene copy and continue producing enough protein; if the cells are short-lived, their therapeutic effect may decline. Correction of long-lived stem-cell populations can provide more durable replenishment of immune cells, but it also demands careful assessment of cell engraftment, gene expression and long-term adverse effects. The source's suggestion that treatment in an early embryo could produce permanence should not be mistaken for the required or preferred clinical route. Modern clinical strategies use specialist somatic-cell approaches.

Other treatment approaches for ADA-related immunodeficiency

The source mentions bone-marrow transplantation and replacement of the missing enzyme. A suitable donor stem-cell transplant may supply cells capable of generating functional ADA-expressing immune lineages, although donor matching and transplant-associated risks matter. Enzyme replacement therapy supplies functional ADA activity and can improve metabolic conditions, but regular treatment may be needed. Gene therapy can instead introduce a functional ADA gene into patient-derived cells. In specialised care, the relative advantages depend on donor availability, condition severity, treatment access and safety.

Clinical progress has extended beyond the early lymphocyte experiment. An authorised European gene-therapy product for ADA-SCID uses genetically modified patient-derived CD34-positive stem/progenitor cells for selected patients without a suitable matched family donor. This illustrates why long-lived corrected cell lineages can be more durable than repeatedly infusing transiently corrected lymphocytes. Regulatory approval applies to defined indications and monitoring conditions; it is not evidence that gene therapy can already cure every inherited disorder.

Quick Quiz